荷兰arGEN-X
arGEN-X公司是一家荷兰生物制药公司，专注于开发人源化抗体药物，核心技术是其专有的抗体制备平台技术。该技术平台产生的单克隆抗体，与人类种系有同源性，是靶向治疗人类疾病的好工具

 Innovative technology at the core of our transforming role in the human therapeutic antibody space. The SIMPLE Antibody™ platform is a limitless source of extremely high quality human antibodies which modulate the function of any disease target, including complex receptors and highly conserved targets. Unprecedented choice of antibody leads with intrinsic drug qualities dramatically increases the efficiency of antibody discovery and success in development.
Proof of the outstanding productivity of our platform is the speed at which we are progressing our pipeline of five therapeutic antibody programs, addressing cancer, autoimmune and inflammatory indications, into preclinical development. Every human antibody in our pipeline has been generated in vivo without in vitro affinity maturation. As fully human antibodies of outstanding potency and consistent manufacturability, SIMPLE Antibody™-based products come with greatly reduced development risk.

The SIMPLE Antibody™ platform is protected by patents with broad claims and freedom to address any disease target of interest.

Since our establishment in 2008, our capabilities and potential have attracted €44 million from leading life science investors and €4.1 million in non-dilutive grants.

In January 2011, we signed our first strategic partnership with Eli Lilly & Company, for the discovery and development of novel human antibodies.